26th Jul 2007 11:00
AstraZeneca PLC26 July 2007 AstraZeneca Development Pipeline26 July 2007 Line Extensions Compound Mechanism Area under investigation Phase Estimated Filing MAA NDACardiovascularAtacand angiotensin II antagonist diabetic retinopathy III 2009 2009Atacand Plus angiotensin II antagonist / 32/12.5 mg, 32/25 mg for III 2H 2008 thiazide diuretic hypertensionCrestor statin atherosclerosis III Approved FiledCrestor statin outcomes CHF III 1H 2008 1H 2008Crestor statin outcomes End Stage Renal III 2009 2009 DiseaseGastrointestinalNexium proton pump inhibitor NSAID GI side effects - III Promotable* Filed symptom resolutionNexium proton pump inhibitor NSAID GI side effects - III Launched Filed ulcer healingNexium proton pump inhibitor peptic ulcer bleeding III 1H 2008 1H 2008Nexium Sachet proton pump inhibitor GERD III Filed LaunchedformulationNexium proton pump inhibitor extra-oesophageal reflux II >2009** >2009** diseaseNexium low dose proton pump inhibitor low dose aspirin III 2009aspirin combination associated peptic ulcer NeuroscienceSeroquel XR D2/5HT2 antagonist schizophrenia III Filed ApprovedSeroquel D2/5HT2 antagonist bipolar maintenance III Q4 2007 FiledSeroquel D2/5HT2 antagonist bipolar depression III Q4 2007 ApprovedSeroquel XR D2/5HT2 antagonist generalised anxiety III 2H 2008 1H 2008 disorderSeroquel XR D2/5HT2 antagonist major depressive III 2H 2008 1H 2008 disorderSeroquel XR D2/5HT2 antagonist bipolar mania III 1H 2008 1H 2008 Seroquel XR D2/5HT2 antagonist bipolar depression III 1H 2008 Q4 2007 Oncology & InfectionFaslodex oestrogen receptor 1st line advanced breast III >2009 >2009 antagonist cancerFaslodex oestrogen receptor adjuvant III >2009 >2009 antagonistFluMist (MedImmune) live, attenuated, intranasal influenza III 1H 2008 Filed influenza virus vaccine * Authorities stated these symptoms were already captured within the GERD label.Text stating "No clinical interaction with naproxen or rofecoxib" was approved. **Project Extraesophageal reflux disease (reflux asthma) will be completed butwill not result in a regulatory filing. Line Extensions (continued) Compound Mechanism Area under investigation Phase Estimated Filing MAA NDARespiratory & InflammationSymbicort Turbuhaler inhaled steroid/fast onset, Symbicort Maintenance III Launched long-acting ss2 agonist and Reliever Therapy for asthma (SMART)Symbicort pMDI inhaled steroid/fast onset, asthma III Filed* Launched** long-acting ss2 agonist Symbicort pMDI inhaled steroid/fast onset, COPD III Filed* 1H 2008 long-acting ss2 agonist * To be supplemented in 2008 with data supporting two additional strengths** US approval based on 12 years and above NCE's Phase III Compound Mechanism Area under Phase Estimated Filing investigation MAA NDACardiovascularAZD6140 ADP receptor antagonist arterial thrombosis III >2009 >2009Saxagliptin dipeptidyl peptidase-4 diabetes III 2009 1H 2008 (DPP-4) inhibitorDapagliflozin sodium-glucose diabetes III >2009 >2009 cotransporter-2 (SGLT2) inhibitorOncology & InfectionZactima VEGF/EGF TKI inhibitor with NSCLC III 2H 2008 2H 2008 RET kinase activity Recentin VEGF signalling inhibitor NSCLC and CRC II/III >2009 >2009 (VEGFR-TKI)Recentin VEGF signalling inhibitor recurrent glioblastoma III >2009 >2009 (VEGFR-TKI)ZD4054 endothelin A receptor hormone resistant III >2009 >2009 antagonist prostate cancerMotavizumab humanized monoclonal antibody RSV prevention III 2009 4Q 2007(MedImmune) NCE's Phases I and II Compound Mechanism Area under investigation Phase Estimated Filing MAA NDACardiovascularCrestor/fibrate statin + fibrate fixed dyslipidaemia II 2009 combinationAZD0837 thrombin inhibitor thrombosis II >2009 >2009AZD1175 diabetes/obesity I >2009 >2009AZD2207 diabetes/obesity I >2009 >2009AZD1305 antiarrhythmic arrhythmias I >2009 >2009AZD6370 diabetes I >2009 >2009AZD4121 cholesterol absorption dyslipidaemia I >2009 >2009 inhibitorGastrointestinalAZD9056 ion channel blocker (P2X7) inflammatory bowel II >2009 >2009 diseaseAZD3355 inhibitor of transient lower GERD II >2009 >2009 oesophageal sphincter relaxations (TLESR)NeurosciencePN-400 naproxen + esomeprazole signs and symptoms of OA II >2009 2009 and RA AZD3480 neuronal nicotinic receptor cognitive disorders in II >2009 >2009 agonist schizophreniaAZD3480 neuronal nicotinic receptor Alzheimers II >2009 >2009 agonistAZD2327 enkephalinergic receptor anxiety & depression I >2009 >2009 modulatorAZD5904 enzyme inhibitor multiple sclerosis I >2009 >2009AZD1080 Alzheimers I >2009 >2009AZD3783 anxiety and depression I >2009 >2009 AZD3241 Parkinson's disease I >2009 >2009 AZD6765 depression I >2009 >2009 AZD0328 Alzheimers I >2009 >2009 AZD1940 nociceptive and I >2009 >2009 neuropathic pain Phases I and II (continued) Oncology & InfectionZactima VEGF/EGF TKI inhibitor with medullary thyroid II 2009 2009 RET kinase activity cancer CytoFab anti-TNF-alpha polyclonal severe sepsis II >2009 >2009 antibodyAZD6244 MEK inhibitor solid tumours II >2009 >2009(ARRY-142886)CAT-3888 recombinant immunotoxin hairy hairy cell leukemia II >2009 >2009 cellAZD2281 PARP inhibitor breast cancer II >2009 >2009EBV vaccine* PTLD II >2009 (MedImmune)AZD0530 SRC kinase inhibitor solid tumours and I >2009 >2009 haematological malignanciesAZD1152 aurora kinase inhibitor solid tumours and I >2009 >2009 haematological malignanciesAZD4769 solid tumours I >2009 >2009AZD4877 solid tumours I >2009 >2009AZD8931 solid tumours I >2009 >2009AZD7762 solid tumours I >2009 >2009AZD8330 MEK inhibitor solid tumours I >2009 >2009(ARRY-424704)CAT-8015 recombinant immunotoxin haematological I >2009 >2009 malignanciesAZD2836 (Arrow) hepatitis C I >2009 >2009MEDI-534 (MedImmune) RSV/PIV-3 vaccine intranasal immunisation I >2009MEDI-560 (MedImmune) PIV-3 vaccine intranasal immunisation I >2009H5N1 (MedImmune) pandemic influenza I TBA TBA vaccineMEDI-524 (Motavizumab) MAb targets F-Protein early & late treatment I >2009(MedImmune) of disease in paeds > 1 yrMEDI-561 (MedImmune) HSP 90 inhibitor solid tumours I >2009MEDI-538 (MedImmune) CD19 B cells leukemia/lymphoma I >2009MEDI-564 F protein inhibitor RSV treatment I >2009 (MedImmune) *Partnered products Phases I and II (continued) Respiratory & InflammationAZD9056 ion channel blocker (P2X7) rheumatoid arthritis II >2009 >2009AZD1981 asthma II >2009 >2009AZD5672 rheumatoid arthritis II >2009 >2009MEDI-528 (MedImmune) anti-IL-9 antibody asthma II >2009AZD4818 COPD I >2009 >2009CAT-354 anti-IL-13 antibody asthma I >2009 >2009AZD5904 COPD I >2009 >2009AZD1744 COPD I >2009 >2009AZD1236 COPD I >2009 >2009AZD9668 COPD I >2009 >2009MEDI-563 (MedImmune) anti-IL-5R antibody asthma I >2009MEDI-545 (MedImmune) humanised antibody SLE, Myositis I >2009Pneumococcal vaccine * streptococcus I >2009(MedImmune) pneumoniae * Partnered products NCE's Pre Clinical Compound Mechanism Area under Phase Estimated Filing investigation MAA NDACardiovascularAZD8593 haemostasis PC >2009 >2009AZD1283 thrombosis PC >2009 >2009AZD5861 dyslipidaemia PC >2009 >2009AZD1656 diabetes/obesity PC >2009 >2009AZD3988 diabetes/obesity PC >2009 >2009AZD3118 arrhythmias PC >2009 >2009 GastrointestinalAZD2066 GERD PC >2009 >2009AZD5329 functional GI disease PC >2009 >2009 NeuroscienceAZD3102 Alzheimers PC >2009 >2009AZD8797 multiple sclerosis PC >2009 >2009AZD2066 analgaesia PC >2009 >2009AZD6280 anxiety PC >2009 >2009AZD2624 schizophrenia PC >2009 >2009AZD1386 analgaesia PC >2009 >2009AZD3043 GABA-A receptor modulator short acting PC >2009 >2009 anaestheticAZD7903 analgaesia PC >2009 >2009AZD1704 analgaesia PC >2009 >2009AZD7325 anxiety PC >2009 >2009 Pre Clinical (continued) Compound Mechanism Area under Phase Estimated Filing investigation MAA NDAOncology & InfectionAZD9935 VEGF signalling inhibitor solid tumours PC >2009 >2009 (VEGFR-TKI)AZD0424 SRC kinase inhibitor solid tumours PC >2009 >2009AZD5180 anti-angiogenic solid tumours PC >2009 >2009AZD1845 solid tumours PC >2009 >2009AZD9468 solid tumours PC >2009 >2009AZD2932 solid tumours PC >2009 >2009CAT-5001 recombinant immunotoxin solid tumours PC >2009 >2009AZD6918 solid tumours PC >2009 >2009AZD4992 PC >2009 >2009AZD5099 infection PC >2009 >2009AZD1480 range of tumours PC >2009 >2009AZD6302 MRSA PC >2009 >2009AZD8055 range of tumours PC >2009 >2009AZD7295 (Arrow) hepatitis C PC >2009 >2009AZD6495 range of tumours PC >2009 >2009MEDI-557 (MedImmune) YTE - extended half-life RSV RSV Prophylaxis PC >2009 MAbRespiratory & InflammationAZD6067 protease inhibitor COPD PC >2009 >2009AZD6357 osteoarthritis PC >2009 >2009AZD3825 asthma PC >2009 >2009AZD5069 COPD PC >2009 >2009AZD8848 asthma PC >2009 >2009AZD8075 asthma PC >2009 >2009AZD6605 osteoarthritis PC >2009 >2009CAM-3001 rheumatoid arthritis PC >2009 >2009AZD3199 asthma/COPD PC >2009 >2009 MedImmune Pre Clinical Compound Mechanism Area under Phase Estimated Filing investigation MAA NDAOncology & InfectionMEDI-536 hMPV/PIV-3 vaccine respiratory infection PC >2009hMPV MAb hMPV MAb respiratory infection PC >2009MEDI-552 anti-CD20 leukemia/lymphoma PC >2009MEDI-548 anti-EphB4 MAb solid tumours PC >2009MEDI-549 anti-Ephrin B2 MAb solid tumours PC >2009MEDI-555 anti-cMet solid tumours PC >2009MEDI-544 anti-EphA2 BiTE solid tumours PC >2009MEDI-562 hedgehog inhibitor solid tumours PC >2009MEDI-551 anti-CD19 MAb leukemia/lymphoma PC >2009MEDI-547 anti-EphA2 conj solid tumours PC >2009anti CEA BiTE anti-CEA BiTE solid tumours PC >2009PIV-1 vaccine PIV-1 vaccine respiratory infection PC >2009PIV-2 vaccine PIV-2 vaccine respiratory infection PC >2009anti staph HP MAb anti-staph HP MAb infectious disease PC >2009hMPV vaccine hMPV vaccine infectious disease PC >2009anti Candida HP MAb anti-Candida HP MAb infectious disease PC >2009 Respiratory & InflammationMEDI-546 anti-IFNaR MAb inflammation PC >2009MEDI-541 anti-HMGB-1 MAb inflammation PC >2009MEDI-551 anti-CD19 MAb inflammation PC >2009MEDI-552 anti-CD20 MAb inflammation PC >2009MEDI-553 anti-CD22 MAb inflammation PC >2009anti IL6 MAb anti-IL6 MAb inflammation PC >2009anti RAGE MAb anti-RAGE MAb inflammation PC >2009anti ICOS MAb anti-ICOS MAb inflammation PC >2009anti YKL40 MAb anti-YKL40 MAb asthma/COPD PC >2009anti Chitinase MAb anti-Chitinase MAb asthma/COPD PC >2009anti C5a MAb anti-C5a MAb inflammation PC >2009 AstraZeneca Development PipelineDiscontinued Projects vs 1 February 2007 FY Cardiovascular & Gastrointestinal NCE/Line Extension Compound Area under investigationNCE AZD2479 dyslipidaemiaNCE AZD9684 thrombosisNCE AGI-1067 atherosclerosisLE Seloken/Toprol-XL HCTZ combinationNCE AZD6610 dyslipidaemia Neuroscience NCE/Line Extension Compound Area under investigationNCE AZD9272 neuropathic painNCE AZD6538 neuropathic pain Oncology & Infection NCE/Line Extension Compound Area under investigationNCE AZD5896 solid tumoursNCE AZD3646 solid tumours & haematological malignanciesLE Iressa BC breast cancerNCE AZD1689 solid tumoursNCE (MedImmune) MEDI-507 (siplizumab) * PTCL/CTCLNCE (MedImmune) MEDI-553 (anti CD22) * leukemia/lymphomaNCE (MedImmune) MEDI-542* solid tumoursNCE (MedImmune) MEDI-556* solid tumoursLE (MedImmune) Synagis ** RSV Respiratory & Inflammation NCE/Line Extension Compound Area under investigationNCE AZD7928 COPDNCE AZD6703 rheumatoid arthritisNCE AZD1678 asthmaNCE AZD2392 asthmaNCE AZD9215 asthma * Compound entered the pipeline in April 07, but has since been discontinued** Minor activity ongoing, but will not lead to new indication/formulation Comments As disclosure of compound information is balanced by the business need tomaintain confidentiality, information in relation to some compounds listed herehas not been disclosed at this time. Compounds in development are displayed by phase. Abbreviations: PC - Pre-clinical: Candidate Drug accepted for development but not yet administered to man.MAA - Marketing Authorisation Application (Europe).NDA - New Drug Application/Biologics Licensing Application (USA). This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca